zandelisib   Click here for help

GtoPdb Ligand ID: 10627

Synonyms: A35 [WO2012135160A1] | Example 51 [WO2012135160A1] | ME-401 | ME401 | PWT-143 | PWT143
Compound class: Synthetic organic
Comment: The chemical structure of example 51 [WO2012135160A1] [1] is identical to the structure that was submitted to the WHO for the INN zandelisib. In the INN submission zandelisib is designated as a PI3 kinase (PI3K) inhibitor and as an antineoplastic. Patent WO2012135160A1 was submitted by the PI3K inhibitor-focussed pharmaceutical company Pathway Therapeutics. Zandelisib has subsequently been declared as MEI Pharma's lead PI3Kδ inhibitor ME-401 [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 83.71
Molecular weight 576.31
XLogP 5.47
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CN1CCC(CC1)c1ccccc1CC(Nc1nc(nc(n1)n1c(nc2c1cccc2)C(F)F)N1CCOCC1)(C)C
Isomeric SMILES CN1CCC(CC1)c1ccccc1CC(Nc1nc(nc(n1)n1c(nc2c1cccc2)C(F)F)N1CCOCC1)(C)C
InChI InChI=1S/C31H38F2N8O/c1-31(2,20-22-8-4-5-9-23(22)21-12-14-39(3)15-13-21)38-28-35-29(40-16-18-42-19-17-40)37-30(36-28)41-25-11-7-6-10-24(25)34-27(41)26(32)33/h4-11,21,26H,12-20H2,1-3H3,(H,35,36,37,38)
InChI Key WPFUFWIHMYZXSF-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
ME-401 has advanced to clinical evaluation in a number of studies for potential to treat lymphomas.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03768505 Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) Phase 2 Interventional MEI Pharma, Inc.
NCT04533581 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Phase 2 Interventional Kyowa Kirin Co., Ltd.
NCT04517435 ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma Phase 1/Phase 2 Interventional Case Comprehensive Cancer Center
NCT04745832 Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) Phase 3 Interventional MEI Pharma, Inc.
NCT02521389 Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143 Phase 1 Interventional MEI Pharma, Inc. 2